After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
See which stocks are posting big moves after the bell.Market Insiderread more
"I'd love to say that the optimistic universe is most likely to prevail, but the talking heads talk endlessly about how a recession is inevitable," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Novartis's third-quarter core net income rose 4 percent at constant currencies, beating expectations, as the drugmaker said it had made "significant progress" in preparing its Alcon eyecare unit for a possible spinoff by the first half of 2019.
Core net income rose to $3.02 billion, compared to the average analyst estimate of $2.93 billion in a Reuters poll. Sales rose 2 percent to $12.4 billion, compared to the $12.2 billion Reuters poll average.
The Swiss group confirmed its full-year outlook.
On Alcon, where sales rose 7 percent in constant currencies, Novartis said on Tuesday a final decision on the unit's future hinged on continued sales growth and margin improvement over multiple quarters, making potential action "not likely before the first half of 2019".
"The strategic review also indicates that creating a stand-alone company via a capital markets exit could create additional shareholder value," Novartis said in a statement.
"We have also made significant progress on developing a potential capital markets solution, including financial carve-outs, tax and legal entity structuring, and identifying listing and incorporation locations."
Psoriasis drug Cosentyx generated quarterly sales of $556 million, beating market estimates. Sales of heart drug Entresto more than doubled to $128 million but missed market expectations.